S 1117
Alternative Names: Pan-IgG protease-Seismic Therapeutics; S-1117Latest Information Update: 23 Apr 2026
At a glance
- Originator Seismic Bio
- Class Enzymes; Immunoglobulin Fc fragments; Recombinant fusion proteins; Recombinant proteins
- Mechanism of Action Immunoglobulin G degraders; Immunosuppressants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Autoimmune disorders
- Preclinical Idiopathic thrombocytopenic purpura
Most Recent Events
- 24 Oct 2025 Pharmacodynamics data from a preclinical studies in autoimmune disorders presented at the ACR Convergence 2025 (ACR/ARP-2025)
- 09 Mar 2025 Phase-I clinical trials in Autoimmune disorders (In volunteers) in Australia (IV) (NCT06828393)
- 09 Mar 2025 Phase-I clinical trials in Autoimmune disorders (In volunteers) in Australia (SC) (NCT06828393)